Css LLC Il Invests $434,000 in Enovis Co. (NYSE:ENOV)

CSS LLC IL purchased a new position in shares of Enovis Co. (NYSE:ENOV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,900 shares of the company's stock, valued at approximately $434,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd bought a new stake in shares of Enovis in the 4th quarter worth $29,000. Quadrant Capital Group LLC raised its stake in shares of Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares in the last quarter. Quarry LP raised its stake in shares of Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after buying an additional 749 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Enovis by 56.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after buying an additional 1,173 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Stock Up 6.0%

NYSE:ENOV traded up $1.88 during trading hours on Tuesday, hitting $33.44. 770,055 shares of the company's stock traded hands, compared to its average volume of 788,351. The firm has a market cap of $1.91 billion, a P/E ratio of -15.27 and a beta of 1.79. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $51.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The stock's fifty day moving average price is $34.57 and its two-hundred day moving average price is $40.91.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The business's quarterly revenue was up 8.2% compared to the same quarter last year. On average, research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ENOV shares. Canaccord Genuity Group cut their target price on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Finally, Needham & Company LLC cut their target price on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $58.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.